Antiplatelet drugs in cardiovascular prevention: stroke: acute phase and secondary prevention.
(1) In the acute phase of ischaemic stroke in patients free of thrombogenic heart disease, combined treatment with aspirin + moderate-dose unfractionated heparin reduces the risk of relapse and death. Unfractionated heparin at higher anticoagulant doses has an unfavourable risk-benefit ratio. Treatment is controversial in patients with events associated with atrial fibrillation.  (2) After ischaemic stroke in patients free of thrombogenic heart disease, aspirin reduces the risk of relapse and death. Other antiplatelet drugs, the aspirin + dipyridamole combination, ticlopidine and clopidogrel have similar efficacy to aspirin.  (3) The risk-benefit ratio of oral anticoagulant is favourable after ischaemic stroke associated with atrial fibrillation; but it is unfavourable after stroke without thrombogenic heart disease.
D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use; D001146:Arrhythmia, Sinus; D001241:Aspirin / Q000008:administration & dosage / Q000627:therapeutic use; D001281:Atrial Fibrillation; D003362:Cost-Benefit Analysis; D004176:Dipyridamole / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006493:Heparin / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D020521:Stroke / Q000188:drug therapy / Q000517:prevention & control; D013988:Ticlopidine / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000627:therapeutic use
D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors; D004176:Dipyridamole; D006493:Heparin; D013988:Ticlopidine; D001241:Aspirin